India10_pocket-progr..

conversesoilBiotechnology

Dec 3, 2012 (4 years and 9 months ago)

348 views


Pocket Program

Current as of
Saturday, March 16, 2013
.

S
c
hedu
le s
ubject to change
.

Please see final daily schedules posted in the
corridors
.

Sponsors
................................
................................
.....................

3

Advi
sory Committee

................................
................................
....

4

Chronological Listing of Events

................................
...................

5

Alphabetical Listing of
Presenting Companies

...........................

16

Chronological

Listing of Presenting Companies

........................

16

Hotel Map

................................
................................
.................

17

Upcoming BIO Events

................................
...............................

18



2

Pocket Program



BIO represents more than 1,
1
00 biotechnology companies, academic
institutions, state biotechnology cente
rs and related organizations across the
United States and in more than 30 other nations. BIO members are involved
in the research and development of innovative healthcare, agricultural,
industrial and environmental biotechnology technologies. BIO also prod
uces
the annual BIO International Convention, the world’s largest gathering of the
biotechnology industry, along with industry
-
leading innovator and partnering
meetings held around the world.

Published by

Biotechnology Industry Organization

1201 Maryland

Ave., SW, Suite 900

Washington DC, 20024

202
-
962
-
9200

|
www.bio.org

Any portion of this material may be reproduced with attribution to BIO

©

20
10

by the Biotechnology Industry Organization.

Biotechnology Industry Organization

James C. Greenwood, President

and Chief Executive Officer

Emerging Companies and Business Development

Alan F. Eisenberg, Executive
VP
, Emerging Companies & Business
Development

John Craighead, PhD,
Managing
Director, Investor Relations & Business
Development

Jen Welch
,

CMP,

Director,
Meetings & Operations

Wesley Triplett, Director, Business Development Marketing

Bernadette Blake, Manager, Registration & Customer Service

Joe Colangelo, Manager, Business Development

Celia Economides, MPH, Manager, Investor Relations

Rena'e Grant, Manager
, Partnering Programs & Investor Outreach

Amy H. Nguyen, Manager, Investor Relations & Business Development

David Thomas,

Manager, Industry Research & Analysis

Sponsorship and Membership

Amy Finan, Vice President, Corporate Development & Marketing

John Sl
oan, Managing Director, External Relations & Development

Susanna Ling, Director, Sponsorship

Jason Rupp, Director, Membership

Elizabeth Gaskins, Manager, Membership

Beth Rosenkoetter, Manager, Sponsorship

Privacy

In accordance with its Privacy Policy, BIO
does not sell or rent its customer
information or usage data to third parties.


Inaugural BIO

India International Partn
ering Conference

3

Sponsors

BIO DOUBLE HELIX SPO
NSOR

Merck & Co., Inc.

Novo Nordisk

BIO HELIX SPONSORS

Astra
Zeneca

CONFERENCE
SPONSORS

Advinus Therapeutics

Alexandria Real Estate
Equities

Associ
ation of Clinical
Research Organizations
(ACRO)

Aurigene Discovery
Technologies Ltd

Biocon, Ltd

Biogen Idec

BIOTECanada

Connexios Life Sciences Pvt,
Ltd

Ernst & Young

GVK Bioscience

MakroCare

MedT
RACK

Ocimum Biosolutions
, Ltd.

Shook, Hardy & Bacon LLP

Sky
quest Technology Group

Torreya Partners

CONFERENCE SUPPORTER
S

BIOTECanada

Centrum Capital

Fidelity Growth Partners India

OrbiMed Advisors


4

Pocket Program

Advisory
Committee

Dr. Rashmi Barbhaiya

CEO and Managing Director
,
Advinus Therapeutics
Private,

Ltd.

Dr. Simon Bes
t

CEO, Aquapharm, Ltd. and
Chairman
,
Edinburgh BioQuarter

Dr. Vijay Chandru

Chairman and CEO
,
Strand LS &
President, ABLE

Mr. Jim Geraghty

Senior Vice President
,
Genzyme,

Inc.

Mr. William Greene

Managing Director
,
MPM Capital

Mr. Joel Marcus

Chief Executiv
e Officer
,
Alexandria Real Estate
Equities,

Inc.

Mr. Sri Mosur

President and CEO
,
Jubilant
Discovery Services, Inc. and
Jubilant Biosys, Ltd.

Mr. Utkarsh Palnitkar

Executive Director
,
Centrum
Capital, Ltd.

Dr. Jasmin Patel

Managing Director
,
FIL Capital
A
dvisors (India) Private, Ltd.

Dr. Swati Piramal

Vice Chairperson
,
Piramal
Lifesciences, Ltd.

Dr. Hitesh Sharma

Partner & National Life Science
Leader
,
Ernst & Young

Dr. Sunny Sharma

Managing Director, Asia
,
OrbiMed Advisors

Mrs. Kiran Mazumdar Shaw

Chairma
n & Managing Director
,
Biocon, Ltd.

Mr. Sujay J. Shetty

Leader, Pharma Life Sciences
Advisory
,
P
ricewaterhouseCoopers (PwC)

Mr. K.V. Subramaniam

President & CEO
,
Reliance Life
Sciences

Dr. M. Vidyasagar

Cecil and Ida Green (II) Chair
Professor, Erik Jonsso
n School
of Engineering & Computer
Science
,
The University of Texas
at Dallas




Chronological
Listing

of Events

Current as of
Saturday, March 16, 2013
.

Schedule subject to change.

Please see fin
al daily schedules posted in the corridors.

Each corporate presentation is
15

minutes long
.


Profiles of presenting companies can be found on the

C
onference CD
-
ROM and at
www.bio.org/bioindia/profiles
.



C
HRONOLOGI CAL

L
I STI NG OF
E
VENTS

6

Pocket Program

Tuesday, September 21

8:00
AM

6:00
PM


Registrat
ion Open


G. 01

8:00
AM

6:00
PM


Partnering Desk
Open


Halls 1 & 2

8:00
AM

6:00
PM


Internet Café

Open

Halls 1 & 2

9:00
AM

12
:00
PM


BIO One
-
on
-
One Partnering Timeslots Available

G.03

G.06

Tu
esday
,
September 21

12
:
0
0

P
M

1:
30

P
M

W
ELCOMI NG
R
EMARKS AND
K
EYNO
TE
L
UNCHEON

Halls 1 & 2

W
ELCOMING
R
EMARKS
:




V楪ay Chandru, PhD, Cha楲man and CEO
,

Strand LS and
ABLE



A污l E楳enberg, EVP, Emerg楮i Compan楥s and Bus楮iss
Deve汯lment, BIO

K
EYNOTE
S
PEAKERS
:



M.K. Bhan, MBBS, MD, Secretary, Dept of B楯iechno汯ly,
䝯vt of Ind
楡i



Jeremy Lev楮i MD, PhD, Sr VP, Strateg楣 呲ansact楯is
䝲oup, Bristol
-
Myers Squ楢i



K楲in Mazumdar
-
Shaw, Cha楲man and Manag楮i D楲ictor,
B楯ion Ltd.

Who’s Who

M.K. Bahn


Dr. M.K. Bhan is M.B.B.S, M.D. Pediatrics, D. Sc. (Honorary),
Fellow, Indian Natio
nal Science Academy (FNA), Fellow, Academy of
Sciences (F.ASc) and Fellow, Academy of Medical Sciences (F.A.M.S.)

He is recipient of numerous awards: "Shanti Swarup Bhatnagar Award",
1990, for medical sciences, the highest Scientific Award below 45 years o
f
age in Indian Sciences, National Ranbaxy Award, 1990, for Medical
Sciences, Achar Gold Medal of the Indian Academy of Pediatrics, 1984, for
the best original research, S.S. Mishra Award of the National Academy of
Medical Sciences, 1986, for the best unpu
blished research, Biotech Product
and Process Development and Commercialization Award, 2003 and Pollins
Foundation Research Award for US 100,000 (Year 2003).

Dr. Bhan is involved with policy formulation role as: Chairman, WHO Task
Force on child health res
earch, Member, Board of Directors, International
Vaccine Institute, Korea, Chairman, National Task Force on micronutrient
policy, Member, Technical Advisory Group, World Health Organization,
Member, NIH Task Force on Rotavirus Vaccines, Chairman, Maternal
and
Child Health Research, Indian Council of Medical Research, Chairman,
Scientific Advisory Committee, National Institute of Nutrition, India, Member
C
HRONOLOGI CAL
L
I STI NG OF
E
VENTS

Inaugural BIO India International Partnering Conference

7

of the Jury for nearly all major national science awards in India such as
Shanti Swarup Bhatnagar Award,
Birla Science Award and Ranbaxy
National Award, Member, Science and Engineering Research Council,
Department of Science and Technology, India, Member, Medical
Biotechnology Board, Department of Biotechnology, Member, Technical
Advisory Group, Child and Ado
lescent Health Division, World Health
Organization, Geneva, Chairman, National Adaptation Committee, Integrated
Management of Child Health, India, Member, Scientific Advisory Committee,
Indian Council of Medical Research, Advisor to the Drug Regulatory
Aut
hority of India, Member, Scientific Advisory Committee, National Institute
of Enteric Diseases and Cholera, India, Member, Program Advisory
Committee on Medical Biology, Department of Science and Technology,
India, Member, Immunization Advisory Board, Gove
rnment of India. Member,
Scientific Advisory Committee, Tuberculosis Research Centre, India,
Member, Scientific Advisory Committee, National Institute of Epidemiology,
India, Chairman, Committee for Preparation of Strategy for Promotion of
neonatal health
in South East Asia, SEARO.

Vijay Chandru


Dr. Vijay Chandru (PhD, MIT 1982) is an academic
entrepreneur named as the "Technology Pioneer" by World Economic Forum
in 2006. Chandru is founder of Strand Life Sciences and currently serves as
its Chairman and
Chief Executive Officer. Chandru's academic career has
spanned over two decades at Purdue University and the Indian Institute of
Science.

Chandru is the recipient of several awards and honors: Fellow of Indian
Academy of Sciences (1996), MCIT Dewang Mehta
Award for Innovation in
IT (2001), UGC Hari Om Trust award for "Science and Society" (2003), the
President's Medal of INFORMS in 2006, distinguished Alumni award by the
MIT India Program in 2007, and was recognized as the Biospectrum Biotech
Entrepreneur o
f 2007.

Chandru is the elected President (2009

2012) of Association of Biotech led
Enterprises (ABLE), the apex trade body representing the Indian Biotech
industry.

Alan Eisenberg


Mr. Eisenberg serves as Executive Vice President for
Emerging Companies an
d Business Development at the Biotechnology
Industry Organization (BIO). In this role, Eisenberg manages and directs
BIO’s services and advocacy efforts for BIO’s emerging companies, which
comprise approximately 90% of BIO’s membership. This includes capit
al
formation policy and human health policy impacting emerging companies,
BIO’s portfolio of investor and partnering events globally, and BIO’s affinity
purchasing program enrolling over 2000 companies.

Previously at BIO, Eisenberg served in other senior l
eadership roles,
including responsibilities for BIO’s communications function, as well as state
government relations, Board operations, and BIO’s political action
committee.

From March 2001 through October 2004, Eisenberg served as Health and
Economics Pol
icy Advisor to BIO CEO Jim Greenwood during his tenure in
Congress. In this role, Eisenberg was extensively involved in the enactment
of several public laws including the Medical Device User Fee and
Modernization Act (P.L. 107

250), the Best Pharmaceutical
s for Children Act
(P.L. 107

109), and key provisions of the Medicare Modernization Act
(P.L.108

173).

Prior to that, Eisenberg briefly served on the staff of the Senate Health,
Education, Labor and Pensions Public Health Subcommittee as Health
C
HRONOLOGI CAL

L
I STI NG OF
E
VENTS

8

Pocket Program

Policy Advi
sor and also was a legislative assistant for Congressman John
Shadegg (R
-
AZ).

Before coming to Washington, Eisenberg spent four years with Ford Motor
Company in Dearborn, MI, as a research economist and finance manager in
manufacturing. As an economist, Ei
senberg was responsible for conducting
and overseeing the development of analyses relating to a variety of energy,
regulatory and tax matters.

Eisenberg holds a Master in Public Policy degree from Harvard University
(Kennedy School of Government), a Master

of Science in Finance degree
from George Washington University, and a Bachelor of Science degree from
Union College. He is married to Shalla Ross, and they have two daughters,
Michayla and Isabella.

Jeremy Levin


Jeremy Levin has global responsibility to

guide planning for
Bristol
-
Myers Squibb’s overall BioPharma strategy. Additionally, he manages
the resources necessary to evaluate, secure and maintain external
opportunities. His Strategy team integrates input from external and internal
sources to help s
ynthesize the company’s strategic direction, and his
Alliances and Transactions teams are responsible for building and managing
our array of innovative alliances, partnerships and acquisitions


called the
String of Pearls.

Prior to his current role, to wh
ich he was appointed in April 2010, Jeremy
was responsible for shaping and executing the String of Pearls strategy.
Since 2007, he and his team completed 10 major String of Pearls
transactions, including the acquisitions of Adnexus Pharmaceuticals and
Meda
rex Inc.

Prior to joining Bristol
-
Myers Squibb, Jeremy served as global head of
Business Development and Strategic Alliances at the Novartis Institutes of
Biomedical Research. In that capacity, between 2003 and 2007, he and his
team secured hundreds of col
laborations in more than 20 countries. Before
his tenure at Novartis, Jeremy was CEO of Physiome Sciences and Cadus
Pharmaceuticals. He was also managing director of Perseus Capital LLC, a
life sciences venture fund. He has served on the executive committe
es and
boards of several public biosciences companies, as well as the executive
committee of BIO and the boards of the Biotechnology Institute and the New
York Biotechnology Association.

In 2005, Jeremy was awarded the Albert Einstein Award for Contributio
ns to
the Life Sciences. And, under his leadership, Bristol
-
Myers Squibb received
the Allicense Breakthrough Alliance Awards in 2008 and 2009, and the M&A
Atlas Award in 2010 for excellence in mergers and acquisitions.

“I’m proud to work at Bristol
-
Myers S
quibb,” says Jeremy. “It is a very special
company with special people. The company has chosen a differentiated
path, focusing purely on medicines that address serious diseases. It is this
focus


coupled with the outstanding people who work here


that ma
kes us
what we are and leads me to believe we are creating a new paradigm in the
pharmaceutical industry.”

Jeremy Levin was born in South Africa, studied zoology as an undergraduate
and then received his D.Phil. at the University of Oxford. He was awarded
his medical degree (MB BChir) from the University of Cambridge and has
practiced as a physician at several university hospitals, including
Hammersmith Hospital in London. Jeremy is married with two daughters.
Over the course of his career, he has lived in
six countries and three
continents.

C
HRONOLOGI CAL
L
I STI NG OF
E
VENTS

Inaugural BIO India International Partnering Conference

9

Kiran Mazumdar
-
Shaw


A successful technocrat of global standing, Ms.
Shaw heads India’s leading Biotechnology enterprise, Biocon. She is highly
respected in the corporate world and was recently named among TIME
magazine
’s 100 most influential people in the world. Her pioneering efforts in
biotechnology have drawn global recognition both for Indian Industry and
Biocon.

Ms
.

Shaw chairs Karnataka's Vision Group on Biotechnology and also
served on the Board of Science Founda
tion, Ireland. She presently serves
on the Advisory Council of the Government’s Department of Biotechnology
where she has been instrumental in bringing government, industry and
academia together, to chart a clear and progressive growth path for
Biotechnolo
gy in India. She is also part of the Prime Minister’s Council on
Trade & Industry in India and the US
-
India CEO Forum. Ms. Shaw also
serves as Member, Governing Body and General Body of the Indian
Pharmacopoeia Commission, an Autonomous Body of the Governm
ent of
India. She is also a founder member of the Society for the formation of
"Institute for Stem Cell Biology and Regenerative Medicine". Ms. Shaw has
been nominated as Member of the Board of Trade, Directorate General of
Foreign Trade, Ministry of Comme
rce & Industry.

Ms. Shaw is the recipient of several prestigious awards including the Nikkei
Asia Prize, 2009 for Regional Growth, Express Pharmaceutical Leadership
Summit Award 2009 for Dynamic Entrepreneur, the Economic Times
‘Businesswoman of the Year’,

the ‘Veuve Clicquot Initiative For Economic
Development For Asia, Ernst & Young's Entrepreneur of the Year Award for
Life Sciences & Healthcare, ‘Technology Pioneer’ recognition by World
Economic Forum and The Indian Chamber of Commerce Lifetime
Achieveme
nt Award. Her most cherished awards are the national awards,
PADMASHRI (1989) and PADMA BHUSHAN (2005) presented to her by the
President of India, for her pioneering efforts in Industrial Biotechnology.

Ms. Shaw received a graduate honors degree in Zoology

from Bangalore
University (1973) and qualified as a Master Brewer from Ballarat University,
Australia (1975). Ms Shaw also received an honorary Doctorate of Science
in 2004, from her alma mater, Ballarat University, in recognition of her pre
-
eminent contr
ibutions to the field of Biotechnology. She has also been
awarded honorary doctorates from University of Abertay, Dundee, U.K.
(2007), University of Glasgow, U.K. (2008) and Heriot
-
Watt University,
Edinburgh, U.K. (2008).

Under her stewardship, Biocon has
evolved from its inception in 1978 as an
industrial enzymes company to a fully integrated Biopharmaceutical
enterprise encompassing a well balanced business portfolio of products and
services with a research focus on Diabetes, Oncology and Auto
-
immune
dise
ase. During this transition, Biocon has established 2 subsidiaries:
Syngene (1994) to provide development support services for discovery
research and Clinigene (2000) to cater to services in clinical development.

A leading US trade publication, Med Ad News
, in its 2007/08 listings has
ranked Biocon 20th amongst the leading biotechnology companies in the
world and the 7th largest Biotech employer in the world. Biocon also
received the 2009 BioSingapore Asia Pacific Biotechnology Award for Best
Listed Company
.

She is married to John Shaw, a Scotsman and Indophile, who headed a
leading textiles MNC, Madura Coats from 1991

1998 as Chairman and
Managing Director. John Shaw is currently the Vice
-
Chairman, Biocon
Limited.

C
HRONOLOGI CAL

L
I STI NG OF
E
VENTS

10

Pocket Program

Tuesday, September 21

1
:
3
0
PM

5
:00
PM


BIO

One
-
on
-
One Partnering Timeslots Available

G.03

G.06

1
:
3
0
PM

5
:00
PM

Company Presentations

G.01

Tuesday, September 21

5
:
00

P
M

6:30

P
M

P
LENARY
S
ESSI ON

Hall 2

Unique Deal Structures

MODERATOR
:


Karen Bernstein, PhD, Editor
-
in
-
Chief, BioCentury

PANELISTS
:




shm椠Barbha楹a, MD, CE传and Manag楮i D楲ictor,
Adv楮is 周Trapeut楣s Pvt Ltd



Ach楮 䝵pta, Sen楯i V楣e Pres楤int, Corporate Strategy,
䝬Gnmark Pharmaceuticals



Sr椠Mosur, Pres楤int and CEO, Jub楬ant B楯iys Ltd.



Dav楤iN楣ho汳on, PhD, Sr VP and Head, Wor汤l
楤i
L楣ens楮i and Know汥lge Management, Merck & Co., Inc.

周楳 pane氠w楬氠take a deep d楶e 楮to a few of the un楱ie deal structures
deve汯led between US/European and Ind楡i compan楥s to discuss the nuts
and bo汴s of do楮i a drug deve汯lment deal. What sp
ec楦楣 e汥ments were
negot楡ied 楮 the deal to get a汬 part楥i on board? What has gone we汬 for
both parties? What are the lessons learned? Merck’s drug development
deals with both Advinus and Orchid have resulted in milestones. What has
made these arr
angements work? How has both parties matured? What was
the market’s perspective on this deal? Likewise, Jubilant and Glenmark
have been among the most active deal makers in India, though from different
perspectives. Jubilant has created new, innovative
structures in its deals with
Lilly and AZ to in
-
license candidates for development. And, Glenmark has
undertaken unique outlicensing deals of novel compounds that may lead to
the first Indian NDA. Representatives from US/European and Indian
companies will

share their stories to prepare new entities considering
partnerships with Indian companies.

Who’s Who

Rashmi Barbhaiya


Dr. Barbhaiya is an internationally reputed Pharma
executive having extensive global experience in handling diverse aspects of
drug di
scovery and development. He has held several prestigious positions
in leading pharmaceutical companies and brings along an impeccable history
in R&D operations and a successful background in business development
and deal making. Past offices held by Dr. Ba
rbhaiya include President of
Research and Development, Ranbaxy Research Laboratories, New Delhi,
India and Vice President in the Pharmaceutical Research Institute, Bristol
-
Meyers Squibb. In his 21 years with BMS and about 2 years with Ranbaxy,
Dr. Barbhaiy
a has been instrumental in discovery and development of
numerous new drugs and drug delivery products. Over his career, Dr.
C
HRONOLOGI CAL
L
I STI NG OF
E
VENTS

Inaugural BIO India International Partnering Conference

11

Barbhaiya has authored numerous publications (about 150) covering a broad
range of therapeutic areas. He obtained his PhD degree in
Clinical
Pharmacology from the St. Bartholomew's Hospital Medical College,
University of London and combined his education through post
-
doctoral
training at the University of Florida and University of Wisconsin.


Sri Mosur


Sri has been involved in devel
oping research and manufacturing
alliances between India China and the global pharmaceutical Industry for
over 19 years. Having extensive hands on experience of the emerging
markets, Sri has a very good perspective of the capabilities in the emerging
marke
ts of India and China and the needs of the global pharmaceutical
industry.

His expertise includes developing integrated and functional alliances in
collaborative research and development alliances. Having worked with major
pharmaceutical, biotech and ventu
re funding companies in the last two
decades, Sri brings a very good perspective of the needs, capabilities and
the potential synergies between the mature and emerging markets. Sri has
directed, strategically and functionally, multiple pioneering alliances

between
these two markets since 1995.

Sri's past and current obligations include: Stint with Indian Pharmaceutical
industry, early in his career, Partner in Austin Chemical Company Inc, a
Chicago based company involved in outsourcing alliances for major p
harma,
Strategic consulting to a large mid
-
western pharma in setting up their
research and development strategy in India, the board of Pharma Innovation
LLc, a biotech offshoot from Columbia university. NY, Board of Muroplex Inc.

At Jubilant, reporting to
the Board, Sri is responsible for leading collaborative
research and development vertical with Jubilant.

Over the last decade, Sri has been involved quite extensively in promoting
alliances within the industry, to include multiple speaking assignments in
g
lobal forums to include:


NAPM, DCAT, SOCMA
-
Informex, ISM, Harvard
Business School, Wharton Business School, Bio, and multiple other industry
and government forums.

Sri is a Chemical engineer and apart from developing successful business
models, Sri also h
as extensive functional experience in global regulatory
compliance, project management and chemical process development.


Tuesday, September 21

6
:
3
0

P
M

9
:
00

PM

Gala
Reception

Outside Lawn

C
HRONOLOGI CAL

L
I STI NG OF
E
VENTS

12

Pocket Program

Wedne
sday
,
September 22

8
:00
AM

6:00
PM


Registration Open

G. 01

8
:
00
AM

6:00
PM


Partnering Desk
Open

Halls 1 & 2

7:00
AM

6:00
PM


Internet Café

Open

Halls 1 & 2

9
:00
AM

12
:00
PM


Company Presentations

G. 01

9
:00
AM

12
:00
PM


BIO One
-
on
-
One Partnering Timeslots Available

G.03

G.06

Wednesday, September 22

12:
0
0

PM

1:30

PM

P
LENARY
L
UNCHEON

Halls 1 & 2

IP and Tech Transfer in India

INTRODUCTION
:

Samir K. Brahmachari, PhD, Director, Council of
Scientific and Industrial Research (CSIR)

MODERATOR
:

Thomas Moga, Shook, Hardy and Bacon LLP

PANELISTS
:



Prav楮iAnand, Manag楮i Par
tner, Anand and Anand



Deepam Mishra, CE伬 椲楮d楡



Arundeep Pradham, Assoc楡te VP, 呥ch 呲ansfer and
Bus楮iss Deve汯lment, 佲egon State Un楶ers楴y



S.R. Rao, D楲ictor, Dept of B楯techno汯ly, 䝯vt of Ind楡

B楯iechno汯ly 楮iovat楯is and hence a v楢iant b楯ie
chno汯ly 楮iustry
beg楮i 楮 research 污lorator楥i. The U.S. 汥lrned over 30 years ago to
汥lerage pub汩c汹 funded research to deve汯l cutt楮i edge products and
techno汯l楥s and 楮ithe process to create m楬汩ons of h楧i pay楮i 橯js. It was
ab汥lto accompl
ish this through an eff楣楥it techno汯ly transfer syste洠
governed by the forward 汯lk楮i Bayh
-
Do汥lAct. Ind楡 is also 汯lk楮i to grow
楴s b楯iechno汯ly 楮iustry by imp汥ment楮i its own vers楯i of the U.S. Bayh
-
Do汥lAct. 周T b楬氠is current汹 under cons楤
erat楯i by the Ind楡i Parl楡ment.

A panel of government, academic and industry experts will discuss India’s
proposed Utilization of Public Funded Intellectual Property Bill and its
implication for translating research into cutting edge products. The panel
will
review the provisions of the bill and will discuss how it will affect foreign
investment, partnership opportunities in India and innovative product
development. The panel will also discuss its impact on the burgeoning
biotechnology industry in India.


C
HRONOLOGI CAL
L
I STI NG OF
E
VENTS

Inaugural BIO India International Partnering Conference

13

Wednesday, September 22

1
:
3
0
PM

3
:
3
0
PM


BIO One
-
on
-
One Partnering Timeslots Available

G.03

G.06

1
:
3
0
PM

3
:
3
0
PM

Company Presentations

G.01

Wednesday, September 22

3:30

P
M

5
:
00

P
M

C
LOSI NG
P
LENARY
S
ESSI ON

Hall 1

Financing of Innovation in India

MODERATO
R
:


Jasmin Patel, PhD, Managing Director, FIL Capital
Advisors

PANELISTS
:



Sr楮椠Akkara橵j Manag楮i D楲icetor, New Leaf Venture
Partners



䝥rhard K汥ment, D楲ictor, Head of Pharma So汵l楯is,
P楲ima氠Healthcare



H楴esh Sharma, Partner and Leader, L楦e Sc楥ice
Pract楣e,
Ernst & Young



Sunny Sharma, MD, Sen楯i Manag楮i D楲ictor, 佲b楍ed
Adv楳ors, LLC



KV Subraman楡i, CFA, Pres楤int and CE伬 Re汩ance L楦e
Sc楥ices

H楳torica汬y perce楶ed as a 汯l cost manufactur楮i center, Ind楡i楳 quick汹
emerg楮i as an 楮iovat楶e
hub for perform楮i and 楮iest楮i 楮iR&D.
Currently a $5B market, India’s biotech business could be poised to double
by 2015. For example, some Indian companies are directly investing in funds
to finance biotech companies (ie. Reliance/MPM Bioventures IV fu
nd). What
other strategies can be employed to foster this growth in innovation and
R&D? This panel will explore both recent case studies and novel approaches
to the funding of innovation in this rapidly emerging market.




Presenting
Companies

Alphabetical
Listing of Presenting Companies

..........................


16

Chronological

Listing of Presenting Companies

.......................


16


Current as of
Saturday, March 16, 2013
.

Please see final daily schedules posted in the corridors.

Each corporate presentation is 1
5 minutes long
.

Profiles of presenting companies can be found on the

Conference CD
-
ROM and at
www.bio.org/bioindia/profiles
.



P
RESENTI NG
C
OMPANI ES

*Patient Advocacy Group/
Non
-
Profit

16

Pocket Program

A
LPHABETI CAL
L
I STI NG


Company N
ame

Day

Time

Aurigene Discovery Technologies, Ltd.

Tues.

1:30 PM

Biocon, LLtd.

Tues.

3:00 PM

Cellworks Research India Pvt. Ltd.

Tues.

1:45 PM

Connexios Life Sciences Pvt. Ltd.

Tues.

2:15 PM

CureVac Gmbh

Wed.

10:30 AM

Dr. Reddy's Laboratories Lim
ited

Tues.

2:00 PM

Ecron Acunova

Tues.

4:45 PM

GangaGen Biotechnologies Pvt. Ltd.

Tues.

3:15 PM

Incozen Therapeutics Pvt. Ltd.

Tues.

2:30 PM

Indus Biotech Pvt. Ltd.

Tues.

3:45 PM

Intas Biopharmaceuticals Limited

Wed.

11:30 AM

Jubilant Biosys Pvt.
Ltd.

Tues.

2:45 PM

Kemwell Pvt. Ltd.

Tues.

3:30 PM

Mitra Biotech Pvt. Ltd.

Tues.

4:15 PM

Novalead Pharma Pvt. Ltd.

Tues.

4:00 PM

Novo Nordisk A/S

Wed.

1:30 PM

Ocimum Biosolutions Limited

Wed.

10:15 AM

Orchid Research Laboratories

Wed.

11:45 AM

S
kyQuest Technology Consulting Pvt. Ltd.

Wed.

10:45 AM

Spectrum Pharmaceuticals, Inc.

Wed.

11:15 AM

Strand Life Sciences Pvt. Ltd.

Wed.

11:00 AM

Wockhardt Limited

Tues.

4:30 PM

C
HRONOLOGI CAL
L
I STI NG

Day

Time

Company Name

Tues.

1:30 PM

Aurigene Disco
very Technologies, Ltd.

Tues.

3:00 PM

Biocon, LLtd.

Tues.

1:45 PM

Cellworks Research India Pvt. Ltd.

Tues.

2:15 PM

Connexios Life Sciences Pvt. Ltd.

Wed.

10:30 AM

CureVac Gmbh

Tues.

2:00 PM

Dr. Reddy's Laboratories Limited

Tues.

4:45 PM

Ecron Ac
unova

Tues.

3:15 PM

GangaGen Biotechnologies Pvt. Ltd.

Tues.

2:30 PM

Incozen Therapeutics Pvt. Ltd.

Tues.

3:45 PM

Indus Biotech Pvt. Ltd.

Wed.

11:30 AM

Intas Biopharmaceuticals Limited

Tues.

2:45 PM

Jubilant Biosys Pvt. Ltd.

Tues.

3:30 PM

Kemwell

Pvt. Ltd.

Tues.

4:15 PM

Mitra Biotech Pvt. Ltd.

Tues.

4:00 PM

Novalead Pharma Pvt. Ltd.

Wed.

1:30 PM

Novo Nordisk A/S

Wed.

10:15 AM

Ocimum Biosolutions Limited

Wed.

11:45 AM

Orchid Research Laboratories

Wed.

10:45 AM

SkyQuest Technology Consultin
g Pvt. Ltd.

Wed.

11:15 AM

Spectrum Pharmaceuticals, Inc.

Wed.

11:00 AM

Strand Life Sciences Pvt. Ltd.

Tues.

4:30 PM

Wockhardt Limited



Inaugural BIO India I
nternational Partnering Conference

17

Hotel Map





U
PCOMI NG
BIO

E
VENTS

18

Pocket Program

9
th

Annual BIO Investor Forum

October
6

7, 2010

|
San Francisco
, CA

-
Europe International Partn
ering Conference

November 15

17, 2010


|

Munich, Germany

Pacific Rim Summit on Industrial Biotechnology and
Bioenergy

December 11

14, 2010


|

Honolulu, HI


Asia International Partnering Conference

January 24

25, 2011


|

Tokyo, Japan


CEO & Investor Co
nference

February 14

15, 2011


|

New York City

-
Europe
Spring 2011

March 14

16, 2011


|

Milan, Italy


Windhover & Pharmaceutical Strategic Outlook

March 30

April 1, 2011


|

New York City


Legislative Day Fly
-
In 2011

May 3

4, 2011 , 2011


|

Washington, D
C

-
L
ES Business Development Course

June, 2011 (Specific dates to be announced)


|

Washington, DC


Executive Presentation Workshop

June, 2011 (Specific dates to be announced)


|

Washington, DC

The Business Forum at the

International Convention

June 28

30, 2011


|

Washington, DC


China International Conference

October, 2011 (Specific dates to be announced)


|

Shanghai, China
N
OTES

Inaugural BIO India I
nternational Partnering Conference

19

N
OTES

20

Pocket Program